Literature DB >> 1321366

Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain.

J M Hill1, A Harris, D I Hilton-Clarke.   

Abstract

Based on the ability of guanine nucleotides to inhibit the binding of vasoactive intestinal peptide to its receptors, a guanosine 5'-triphosphate analog, guanylyl-imidodiphosphate, was used to differentiate two subtypes (or different functional states of a single subtype) of vasoactive intestinal peptide receptor in brain with in vitro autoradiography. In most brain regions, guanylyl-imidodiphosphate reduced vasoactive intestinal peptide binding between 40 and 60%. However, in the supraoptic nucleus, locus coeruleus, interpeduncular nucleus, facial nucleus, olfactory tubercle and periventricular hypothalamic nucleus, 80% or more of vasoactive intestinal peptide binding was inhibited. In other brain regions, including the medial geniculate, olfactory bulbs, and ventral thalamic nuclei, guanylyl-imidodiphosphate had little effect on vasoactive intestinal peptide binding. In liver, lung and intestine it also partly inhibited vasoactive intestinal peptide binding. Electrophoretic analysis of vasoactive intestinal peptide, covalently cross-linked to its receptors in brain membranes, revealed a pair of bands between 44,000 and 52,000 mol. wt, a component at 64,000 mol. wt and another at 92,000 mol. wt. All were displaceable with vasoactive intestinal peptide but guanylyl-imidodiphosphate displaced only the 64,000 mol. wt band suggesting that the GTP-sensitive vasoactive intestinal peptide receptor seen in brain sections has a molecular weight of about 61,000. The differential sensitivity to guanylyl-imidodiphosphate suggests the existence of at least two vasoactive intestinal peptide receptor subtypes in brain, with distinct regional distribution, and may reflect differential coupling to second messenger systems.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321366     DOI: 10.1016/0306-4522(92)90280-f

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain.

Authors:  P Gressens; S Marret; J M Hill; D E Brenneman; I Gozes; M Fridkin; P Evrard
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

Review 2.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

3.  Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent.

Authors:  J M Hill; S K McCune; R J Alvero; G W Glazner; K A Henins; S F Stanziale; J R Keimowitz; D E Brenneman
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

4.  Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.

Authors:  Jolanta B Zawilska; Agnieszka Dejda; Pawel Niewiadomski; Illana Gozes; Jerzy Z Nowak
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation.

Authors:  Nadia Sahir; Douglas E Brenneman; Joanna M Hill
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

6.  Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse.

Authors:  P Gressens; J M Hill; B Paindaveine; I Gozes; M Fridkin; D E Brenneman
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.

Authors:  Jolanta B Zawilska; Pawel Niewiadomski; Jerzy Z Nowak
Journal:  J Mol Neurosci       Date:  2003-04       Impact factor: 3.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.